Sökning: id:"swepub:oai:gup.ub.gu.se/279185" >
Improved Differenti...
Improved Differential Diagnosis of Alzheimer's Disease by Integrating ELISA and Mass Spectrometry-Based Cerebrospinal Fluid Biomarkers
-
Khoonsari, P. E. (författare)
-
Shevchenko, G. (författare)
-
Herman, S. (författare)
-
visa fler...
-
Remnestal, J. (författare)
-
Giedraitis, V. (författare)
-
Brundin, R. (författare)
-
Gunnarsson, M. D. (författare)
-
Kilander, L. (författare)
-
- Zetterberg, Henrik, 1973 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry
-
Nilsson, P. (författare)
-
Lannfelt, L. (författare)
-
Ingelsson, M. (författare)
-
Kultima, K. (författare)
-
visa färre...
-
(creator_code:org_t)
- IOS Press, 2019
- 2019
- Engelska.
-
Ingår i: Journal of Alzheimers Disease. - : IOS Press. - 1387-2877 .- 1875-8908. ; 67:2, s. 639-651
- Relaterad länk:
-
https://content.iosp...
-
visa fler...
-
https://gup.ub.gu.se...
-
https://doi.org/10.3...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background: Alzheimer's disease (AD) is diagnosed based on a clinical evaluation as well as analyses of classical biomarkers: A beta(42), total tau (t-tau), and phosphorylated tau (p-tau) in cerebrospinal fluid (CSF). Although the sensitivities and specificities of the classical biomarkers are fairly good for detection of AD, there is still a need to develop novel biochemical markers for early detection of AD. Objective: We explored if integration of novel proteins with classical biomarkers in CSF can better discriminate AD from non-AD subjects. Methods: We applied ELISA, mass spectrometry, and multivariate modeling to investigate classical biomarkers and the CSF proteome in subjects (n = 206) with 76 AD patients, 74 mild cognitive impairment (MCI) patients, 11 frontotemporal dementia (FTD) patients, and 45 non-dementia controls. The MCI patients were followed for 4-9 years and 21 of these converted to AD, whereas 53 remained stable. Results: By combining classical CSF biomarkers with twelve novel markers, the area of the ROC curves (AUROCS) of distinguishing AD and MCl/AD converters from non-AD were 93% and 96%, respectively. The FTDs and non-dementia controls were identified versus all other groups with AUROCS of 96% and 87%, respectively. Conclusions: Integration of new and classical CSF biomarkers in a model-based approach can improve the identification of AD, FTD, and non-dementia control subjects.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Neurologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Neurology (hsv//eng)
Nyckelord
- Alzheimer's disease
- cerebrospinal fluid
- ELISA
- mass spectrometry
- mild cognitive impairment
- mild cognitive impairment
- apolipoprotein-a-i
- clinical-diagnosis
- csf
- biomarkers
- protein
- identification
- neurogranin
- proteomics
- consensus
- workflow
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Khoonsari, P. E.
-
Shevchenko, G.
-
Herman, S.
-
Remnestal, J.
-
Giedraitis, V.
-
Brundin, R.
-
visa fler...
-
Gunnarsson, M. D ...
-
Kilander, L.
-
Zetterberg, Henr ...
-
Nilsson, P.
-
Lannfelt, L.
-
Ingelsson, M.
-
Kultima, K.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Neurologi
- Artiklar i publikationen
-
Journal of Alzhe ...
- Av lärosätet
-
Göteborgs universitet